N@N

Bioniche Strengthens its International Patent Portfolio for its MCC &; Oligonucleotide Technology Platforms

_{//health-fitness.news-articles.net/content/2010/ .. ts-mcc-oligonucleotide-technology-platforms.html}
^{Published in Health and Fitness on Thursday, June 17th 2010 at 4:11 GMT by Market Wire}  

 1. "Composition and Method for Regulating Cell Proliferation and Cell Death" granted in Japan as Patent No. 4335435; and in Canada as Patent No. 2299548. 2. "Composition and Method for the Treatment of Bladder Cancer" granted in Japan as patent No. 4426067. 3. "Chemotherapeutic Composition and Method" granted in Japan as Patent No. 4380922; and has been allowed in Canada. 4. "Method for the Treatment of Inflammation": A "Notice of Decision to Grant a Patent" has been received for the Japanese application. 

 1. 'Therapeutically Useful Synthetic Oligonucleotides' granted in Europe as EP Patent No. 1867718 (validated in: Switzerland, Germany, Denmark, Spain, France, Great Britain and Italy). This application has also been granted in Israel as Patent No. 150196. 2. "Modulation of FAS and FASL Expression" issued in the US as Patent No. 7662792. 3. "Oligonucleotide Compositions and Their Use to Induce Differentiation of Cells" granted in Japan as Patent No. 4460220; and in South Korea as Patent No. 913860. 4. "Conformation-Activity Relationship of Apoptosis-Inducing Phosphodiester Oligonucleotides" granted in South Korea as Patent No. 943567; and a "Notice of Decision to Grant a Patent" has been received for the Japanese application. 5. "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides" granted in Japan as Patent No. 4405259; and issued in the U.S. as Patent No. 7635686.